Michael H. Silverman
Petah Tiqwa, M, Israel
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Efficacy and safety of piclidenoson in plaque psoriasis: Results from a randomized phase 3 clinical trial (COMFORT-1).
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: July 30, 2023
A long‑term complete response to namodenoson in liver cancer with Child‑Pugh B cirrhosis: A case report.
Journal: Experimental and therapeutic medicine
Published: June 29, 2023
Targeting the A3 adenosine receptor to treat hepatocellular carcinoma: anti-cancer and hepatoprotective effects.
Journal: Purinergic signalling
Published: October 31, 2022
Editorial: targeting aberrant hepatic inflammation for treatment of non-alcoholic steatohepatitis-authors' reply.
Journal: Alimentary pharmacology & therapeutics
Published: January 29, 2022
Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis.
Journal: Alimentary pharmacology & therapeutics
Published: July 13, 2021
Inhibition of IL-17 and IL-23 in Human Keratinocytes by the A3 Adenosine Receptor Agonist Piclidenoson.
Journal: Journal of immunology research
Published: December 19, 2017
A phase I clinical trial of dTCApFs, a derivative of a novel human hormone peptide, for the treatment of advanced/metastatic solid tumors.
Journal: Molecular and clinical oncology
Published: March 31, 2017
Treatment of Plaque-Type Psoriasis With Oral CF101: Data from a Phase II/III Multicenter, Randomized, Controlled Trial.
Journal: Journal of drugs in dermatology : JDD
Published: August 19, 2016
Showing 1-10 of 10
Last Updated: 09/26/2026